legislative measures to at least
continue the two-year moratorium
on the tax that expired December
2017 saw a further decline in deal
value from2016, resulting from
global economic and political
uncertainty. Large deals that were
announced in 2017 tended to be
focused on traditional acquisitions
that were within the core compe-tencies of the acquirer.
According to Thomson Reuters
data, the largest deal through Q3
2017 is Becton Dickinson & Co.
acquiring CR Bard in April, in
a deal worth $24.2B. In biotech,
Gilead Sciences Inc. acquired Kite
Pharma Inc. for$11.1B. In pharmaceuticals, ThermoFisher Scientific, Inc. acquired Patheon NV
(99.0066% interest) for $7.2B39.
In 2017, the total value of medtech
venture financing deals rose
considerably, despite the number
of deals falling40. Finding new
technologies to fuel future growth
could be a challenge for large, es-
tablished medtech companies41.
Exponential advances in technology make medtech ripe for innovation. Sensors, analytics, AI, and
other digital health technologies
are converging with medtech.
Companies have an opportunity
to create new business models and
pivot from product developers to
solution providers. Digital health
technologies appear to be attracting more venture capital investment than traditional medtech
Figure 4. Top 15 prescription drug & OTC therapy categories by worldwide sales, 2016-2022
Source: EvaluatePharma, 2017